Answers are grounded in this paper and cite their sources.
Examines inhalation safety and proposes a transparency standard for terpene enhancement in cannabis products, indicating pathways for industry improvement.
The commercial cannabis industry is undergoing a structural shift. As of early 2026, pre-rolled joints and infused products have overtaken whole flower as the top-grossing product category in North America. This shift relies heavily on the utilization of bulk trim and lower-tier biomass, necessitating post-harvest flavor enhancement — primarily through the application of terpene sprays. However, the rapid adoption of this practice has outpaced consumer education and regulatory frameworks, leading to a rising controversy over "sprayed weed" and concerns regarding inhalation safety. This paper examines the combustion chemistry of botanical terpenes, the avoidable toxicant risks associated with carrier oils (PG/PEG) and aerosol propellants, and the economic drivers of the pre-roll market. It builds upon the application protocols and formulation standards established in the authors' prior publication on botanical terpene spray application. We propose a "Transparency Standard" for the industry: affirming that post-harvest terpene enhancement is a necessary agricultural practice that can eliminate avoidable inhalation risk when executed with pure botanical compounds, mechanical atomization, and full consumer disclosure. https://terpsusa.com/pages/ultimate-terpene-spray-guide/
No takes yet. Share an insight, caveat, or question.
Kenneth Fry (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: